Positions

Overview

  • Dr. Geldmacher graduated magna cum laude from the University of Rochester (New York) with his B.A. in Biology and Psychology. He obtained his M.D (with Certificate in Academic Research) from the State University of New York Health Science Center at Syracuse. He undertook his training in Neurology at Case Western Reserve University and completed a postdoctoral fellowship in Behavioral Neurology at the University of Florida.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial 2019
    2019 Description of Process and Content of Online Dementia Coaching for Family Caregivers of Persons with Dementia. 2019
    2019 Alabama brief cognitive screener: Utility of a new cognitive screening instrument in a memory disorders clinic 2019
    2017 Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease 2017
    2016 Glucocerebrosidase, Parkinson disease, and the “senses and intellect” 2016
    2016 Qualitative assessment of self-identity in people with advanced dementia 2016
    2014 Can a Memory Club Help Maintain Cognitive Function? A Pilot Investigation 2014
    2014 Implications of early treatment among Medicaid patients with Alzheimer's disease 2014
    2013 Family composition and expressions of family-focused care needs at an academic memory disorders clinic 2013
    2013 Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: An evidence-based approach 2013
    2013 Pre-diagnosis excess acute care costs in alzheimer's patients among a US medicaid population 2013
    2013 High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines 2013
    2012 Challenges and opportunities for characterizing cognitive aging across species 2012
    2012 Characterizing cognitive aging in humans with links to animal models 2012
    2012 Characterizing healthy samples for studies of human cognitive aging 2012
    2012 Parkinson disease: Research update and clinical management 2012
    2012 Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: A subgroup analysis in patients already taking or not taking concomitant memantine 2012
    2012 Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease 2012
    2011 Family quality of life in dementia: A qualitative approach to family-identified care priorities 2011
    2011 Targets of the peroxisome proliferator - activated receptor γ agonist trials for the prevention of Alzheimer disease: Reply 2011
    2011 A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with alzheimer disease 2011
    2010 Alzheimer disease prevention: Focus on cardiovascular risk, not amyloid? 2010
    2008 Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review 2008
    2008 Vascular myelopathies 2008
    2007 Acetylcholinesterase inhibitors for Alzheimer's disease 2007
    2007 MR tractography depicting damage to the arcuate fasciculus in a patient with conduction aphasia [6] 2007
    2007 Treatment guidelines for Alzheimer's disease: Redefining perceptions in primary care 2007
    2006 Realistic expectations for treatment success in Alzheimer's disease 2006
    2006 Conduction aphasia as a function of the dominant posterior perisylvian cortex: Report of two cases 2006
    2005 Erratum: Donepezil (Aricept®) for the treatment of Alzheimer's disease and other dementing conditions (Expert Review of Neurotherapeutic (January 2004) 4, 1 (5-16)) 2005
    2005 The cost benefit to health plans of pharmacotherapy for Alzheimer's disease. 2005
    2004 Dementia with Lewy bodies: Diagnosis and clinical approach 2004
    2004 Fulfilling expectations 2004
    2004 Maintaining patients with Alzheimer's disease in the home environment 2004
    2004 Differential diagnosis of dementia syndromes. 2004
    2004 Differential diagnosis of dementia syndromes 2004
    2004 Donepezil (Aricept®) for treatment of Alzheimer's disease and other dementing conditions 2004
    2004 Interdisciplinary approaches to Alzheimer's disease management 2004
    2003 Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician. 2003
    2003 Visuospatial dysfunction in the neurodegenerative diseases 2003
    2003 Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial 2003
    2003 Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease 2003
    2003 Alzheimer's disease: current pharmacotherapy in the context of patient and family needs. 2003
    2003 Development of a scale to predict decline in patients with mild Alzheimer's disease 2003
    2003 Donepezil in Vascular Dementia: A Viewpoint 2003
    2003 Visuospatial dysfunction in the neurodegenerative diseases. 2003
    2002 Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias 2002
    2002 Cost-effective recognition and diagnosis of dementia 2002
    2002 Medication use in Alzheimer's disease and healthy aging: Results from a research registry 2002
    2002 Quality of Life and Deficit Identification in Dementia 2002
    2001 Apathy in Alzheimer's disease 2001
    2001 DNA replication precedes neuronal cell death in Alzheimer's disease 2001
    2001 Contemporary drug treatment 2001
    2001 Providing care for the caregiver 2001
    2001 Open-label, multicenter, phase 3, extension study of the safety and efficacy of donepezil in patients with Alzheimer disease 2001
    2000 Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons 2000
    2000 Conflicting priorities in Alzheimer's care, primary care, and managed care: Who pays the price? 2000
    2000 Effects of stimulus properties and age on random-array letter cancellation tasks 2000
    1999 Age effects on random-array letter cancellation tests 1999
    1999 Spatial aspects of letter cancellation performance in arabic readers 1999
    1999 Three-dimensional neglect phenomena following right anterior choroidal artery infarction 1999
    1998 Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain 1998
    1998 Clock drawing test in very mild Alzheimer's disease 1998
    1998 Stimulus characteristics determine processing approach on random array letter-cancellation tasks 1998
    1998 The effect of character and array type on visual spatial search quality following traumatic brain injury 1998
    1997 Activities of daily living as an outcome measure in clinical trials of dementia drugs: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines 1997
    1997 Clinical experience with donepezil hydrochloride: A case study perspective 1997
    1997 Ethical issues in dementia drug development: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines 1997
    1997 Objective psychometric tests in clinical trials of dementia drugs: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines 1997
    1997 Donepezil (aricept) therapy for alzheimer's disease 1997
    1997 Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's disease assessment scale that broaden its scope 1997
    1997 Enhancing recovery from ischemic stroke 1997
    1997 Differential diagnosis of Alzheimer's disease 1997
    1997 Effect of stimulus number, target-to-distractor ratio, and motor speed on visual spatial search quality following traumatic brain injury 1997
    1997 Treatment of functional decline in adults with down syndrome using selective serotonin-reuptake inhibitor drugs 1997
    1996 Current concepts: Evaluation of dementia 1996
    1996 Effects of stimulus number and target-to-distractor ratio on the performance of random array letter cancellation tasks 1996
    1996 Executive functions and Alzheimer's disease: Problems and prospects 1996
    1995 Letter cancellation performance in alzheimer’s disease 1995
    1994 Pharmacotherapy for Alzheimer's disease 1994
    1994 Fluoxetine in dementia of the Alzheimer's type: Prominent adverse effects and failure to improve cognition [1] 1994
    1994 Spatial performance bias in normal elderly subjects on aletter cancellation task 1994
    1994 Visual field influence on radial line bisection 1994
    1993 Nonoptic aphasia: Aphasia with preserved confrontation naming in alzheimer's disease 1993

    Chapter

    Year Title Altmetric
    2016 Pharmacotherapy of cognition.  56-79. 2016
    2012 Medical and neurological causes of dementia, Part I.  737-756. 2012

    Research Overview

  • Alzheimer's disease and related disorders
    Meaningfulness of outcomes in Alzheimer's therapeutics
    Visual and spatial processing in aging and neurological disease.

    • Principal Investigator On

  • Alzheimer's Clinical Trials Consortium (ACTC) (U24)  awarded by University of Southern California 2017 - 2022
  • Private Grant  awarded by Genentech 2018 - 2022
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2022
  • Private Grant  awarded by ABBVIE INC 2018 - 2022
  • Private Grant  awarded by ABBVIE INC 2017 - 2022
  • Private Grant  awarded by BIOGEN, INC. 2018 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Examining the Clinical Workflow and Outcomes of Intergrating Health Information Technology to Educate and Support Dementia Caregivers  awarded by UNIVERSITY OF ALABAMA (TUSCALOOSA) 2018 - 2020
  • Effects of Traumatic Brian Injury and Post-Traumatic Stress Disorder and Alzheimer's Disease on Brain Tau in Vietnam Veterans using ADNI  awarded by University of Southern California 2018 - 2020
  • Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People with Alzheimer Dementia and Traumatic Brain Injury  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2020
  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNl3)  awarded by University of Southern California 2016 - 2020
  • Private Grant  awarded by EISAI, INC. 2013 - 2020
  • Global Alzheimer’s Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease  awarded by University of Southern California 2019 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2015 - 2019
  • Private Grant  awarded by NEURIM PHARMACEUTICALS 2017 - 2019
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2018
  • Private Grant  awarded by ASSUREX HEALTH INC. 2016 - 2018
  • Private Grant  awarded by AVANIR PHARMACEUTICALS, INC. 2016 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Private Grant  awarded by GlaxoSmithKline 2011 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study: A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2015 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - The LEARN Study A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of California, San Diego 2015
  • Private Grant  awarded by Baxter Healthcare Corporation 2012 - 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Alzheimer's Disease Cooperative Study  awarded by University of California, San Diego 2013 - 2015
  • Private Grant  awarded by Baxter Healthcare Corporation 2013
  • Private Grant  awarded by Baxter Healthcare Corporation 2012 - 2013
  • A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer's Disease (CERE 110-3)  awarded by University of California, San Diego 2011 - 2013
  • Private Grant  awarded by Bayer HealthCare 2011 - 2012

    • Investigator On

  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”).  awarded by Washington University 2018 - 2022
  • Obesity Health Disparities Research Center (OHDRC)  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS 2017 - 2022
  • Obesity Health Disparities Research Center (OHDRC) - Investigating the Interconnection of Social Determinants of Health and Racial/Ethnic Disparities in the Care for Alzheimer’s Disease and Related Dementia of Older Adults in the Deep South and the Rest of the United States  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by BIOGEN IDEC, INC. 2017 - 2021
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study  awarded by University of Southern California 2019 - 2020
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2020
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study A Companion Observational Study to Antl-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2016 - 2020
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”)  awarded by THE WASHINGTON UNIVERSITY 2018 - 2020
  • McKnight Brain Aging Registry  awarded by University of Miami 2016 - 2020
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2017 - 2020
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Processing Speed Training to Preserve Driving and Functional Competencies in MCI  awarded by National Institute on Aging/NIH/DHHS 2014 - 2019
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California 2016 - 2018
  • Causes, Treatment, and Prevention of Corticobasal Degeneration  awarded by University of California, San Francisco 2014 - 2018
  • Private Grant  awarded by AVID RADIOPHARMACEUTICALS 2014 - 2018
  • Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study  awarded by American College of Radiology 2016 - 2018
  • Functional Change in Mild Cognitive Impairment  awarded by National Institute on Aging/NIH/DHHS 2010 - 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • Clinical Correlates of Family Quality of Life in Dementia  awarded by ALZHEIMER'S OF CENTRAL ALABAMA 2015 - 2017
  • Private Grant  awarded by C2N DIAGNOSTICS, LLC 2015 - 2016
  • Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)  awarded by University of Southern California 2015 - 2016
  • Alzehimer's Disease Neuroimaging Initiative (ADNI)  awarded by University of California, San Diego 2005 - 2016
  • Private Grant  awarded by Teva Pharmaceuticals 2013 - 2015
  • Private Grant  awarded by CEREVAST THERAPEUTICS, INC. 2013 - 2014
  • A Multi-Center Trial to Evaluate Home Based Assessment Methods for Alzheimer's Disease Prevention Research in People Over 75 Years Old (ADC-030-HBA)  awarded by University of California, San Diego 2012 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2009 - 2013
  • Amyloid Imaging, VMCI, and Analysis for ADNI  awarded by University of California, San Diego 2009 - 2012

    • Teaching Overview

  • I provide clinical teaching in inpatient and outpatient settings to medical students, residents, and postdoctoral trainees.

    • Education And Training

  • Doctor of Medicine, State University of New York Upstate Medical University 1986
  • Bachelor of Arts in Biology, University of Rochester 1982
  • Mount Sinai Medical Center, Internship 1987
  • Case Western Reserve University, Residency 1990
  • University of Florida/Shands Hospital, Postdoctoral Fellowship 1991

    • Full Name

  • David Geldmacher